1. Home
  2. PLX vs MBOT Comparison

PLX vs MBOT Comparison

Compare PLX & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLX
  • MBOT
  • Stock Information
  • Founded
  • PLX 1993
  • MBOT 2010
  • Country
  • PLX United States
  • MBOT United States
  • Employees
  • PLX N/A
  • MBOT N/A
  • Industry
  • PLX Biotechnology: Biological Products (No Diagnostic Substances)
  • MBOT Medical/Dental Instruments
  • Sector
  • PLX Health Care
  • MBOT Health Care
  • Exchange
  • PLX Nasdaq
  • MBOT Nasdaq
  • Market Cap
  • PLX 122.6M
  • MBOT 99.3M
  • IPO Year
  • PLX 1998
  • MBOT N/A
  • Fundamental
  • Price
  • PLX $1.54
  • MBOT $2.63
  • Analyst Decision
  • PLX Strong Buy
  • MBOT Strong Buy
  • Analyst Count
  • PLX 1
  • MBOT 1
  • Target Price
  • PLX $15.00
  • MBOT $9.00
  • AVG Volume (30 Days)
  • PLX 1.2M
  • MBOT 1.3M
  • Earning Date
  • PLX 08-13-2025
  • MBOT 08-13-2025
  • Dividend Yield
  • PLX N/A
  • MBOT N/A
  • EPS Growth
  • PLX N/A
  • MBOT N/A
  • EPS
  • PLX 0.05
  • MBOT N/A
  • Revenue
  • PLX $59,764,000.00
  • MBOT N/A
  • Revenue This Year
  • PLX $65.02
  • MBOT N/A
  • Revenue Next Year
  • PLX $57.34
  • MBOT N/A
  • P/E Ratio
  • PLX $31.98
  • MBOT N/A
  • Revenue Growth
  • PLX 0.18
  • MBOT N/A
  • 52 Week Low
  • PLX $0.82
  • MBOT $0.82
  • 52 Week High
  • PLX $3.10
  • MBOT $3.38
  • Technical
  • Relative Strength Index (RSI)
  • PLX 47.41
  • MBOT 55.29
  • Support Level
  • PLX $1.32
  • MBOT $2.43
  • Resistance Level
  • PLX $1.67
  • MBOT $2.60
  • Average True Range (ATR)
  • PLX 0.11
  • MBOT 0.12
  • MACD
  • PLX 0.04
  • MBOT 0.01
  • Stochastic Oscillator
  • PLX 62.86
  • MBOT 100.00

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

About MBOT Microbot Medical Inc.

Microbot Medical Inc is a clinical-stage medical device company specializing in the research, design and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. It is focused on leveraging its robotic technologies to redefine surgical robotics while improving surgical outcomes for patients. Using its LIBERTY technological platform, the company is developing the first-ever fully disposable robot for various endovascular interventional procedures.

Share on Social Networks: